LifeSplice Pharma Competitors and Similar CompaniesClear all
LifeSplice Pharma's competitors and similar companies include Aerie Pharmaceuticals, Alnylam, Sorrento Therapeutics and ANI Pharmaceuticals.
 LifeSplice Pharma LifeSplice Pharma is a biotechnology company that develops products for the treatment of neurological and non-neurological diseases. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. | |
Founding Date | Founding Date 2011 | Founding Date 2005 | Founding Date 2002 | Founding Date 2006 | Founding Date 1996 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Malvern, US HQ | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations San Diego, US HQ San Diego, US | Locations Baudette, US HQ Oakville, CA Baudette, US | |
Employees | Employees 2 | Employees 3808% increase | Employees 1,32324% increase | Employees 31019% decrease | Employees 33813% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 722.2 m | Valuation ($) 36.5 b | Valuation ($) 1.5 m | Valuation ($) 1.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $883.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) | Cost of goods $677.2m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Net income | Net income N/A | Net income ($74.8m) (FY, 2021) | Net income $313.7m (FY, 2025) | Net income ($577.8m) (FY, 2022) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 388.6m | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View company